Company intelligence / Profile preview
Ennovate Pharma
- Ownership
- Private
- Development stage
- Preclinical
Overview
Ennovate Pharma develops precision therapeutics for autoimmune and inflammatory diseases, focusing on patients who do not respond to current cytokine-based treatments. The company leverages advanced single-cell spatial biology data combined with standard clinical data, analyzed through proprietary AI/ML algorithms, to rapidly identify new drug targets. Its pipeline includes three preclinical antibody programs targeting key immune pathways relevant to refractory disease populations.
- Therapeutic areas
- Immunology
- Modalities
- Monovalent biologics (antibodies)Bifunctional/bispecific biologics (antibodies)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Ennovate Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ennovate Pharma.